Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07001332

ELEVATE High-Risk PCI Pivotal Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
290 (estimated)
Sponsor
Magenta Medical Ltd. · Industry
Sex
All
Age
18 Years – 88 Years
Healthy volunteers
Not accepted

Summary

The ELEVATE III Pivotal Study is a prospective, multi-center, open-label, interventional, randomized, controlled study with an active control group. The study is intended to assess the safety and efficacy of the Elevate™ percutaneous Left Ventricular Assist Device System in patients referred to high-risk percutaneous coronary interventions (HR-PCI).

Detailed description

The Elevate™ percutaneous Left Ventricular Assist Device System is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease. Use of the Elevate™ System in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions.

Conditions

Interventions

TypeNameDescription
DEVICEElevateThe Elevate System is a catheter- mounted, self-expanding and retrievable, continuous-flow pump, designed to unload the left ventricle by actively transporting blood from the left ventricle into the ascending aorta, thus augmenting cardiac output and maintaining systemic arterial pressure during complex/high-risk coronary interventions. Subjects will receive an Elevate prior to their high-risk percutaneous intervention.
DEVICEImpellaSubjects will receive an Impella prior to their high-risk percutaneous intervention.

Timeline

Start date
2025-07-25
Primary completion
2027-03-16
Completion
2027-09-16
First posted
2025-06-03
Last updated
2026-03-17

Locations

28 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07001332. Inclusion in this directory is not an endorsement.